Nedisertib by Merck for Neuroendocrine Tumors: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity.
Let's personalize your content